ISID Home
about ISID | membership | programs | publications | resources | 14th ICID | site map
 
ProMed Home
 
  Navigation
Home
Subscribe/Unsubscribe
Search Archives
Announcements
Recalls/Alerts
Calendar of Events
Maps of Outbreaks
Submit Info
FAQs
Who's Who
Awards
Citing ProMED-mail
Links
Donations
About ProMED-mail
 
Archive Number 20091017.3577
Published Date 17-OCT-2009
Subject PRO/AH/EDR> Influenza pandemic (H1N1) 2009 (72): pneumonia

INFLUENZA PANDEMIC (H1N1) 2009 (72): PNEUMONIA
**********************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

[1]
Date: Fri 16 Oct 2009
Source: The Washington Post [edited]
<http://www.washingtonpost.com/wp-dyn/content/article/2009/10/16/AR2009101601384.html?sub=AR>


Viral pneumonia commoner with swine flu than common flu
-------------------------------------------------------
The World Health Organization (WHO) on Friday [16 Oct 2009] urged doctors 
to treat suspected swine flu cases as quickly as possible with antiviral 
drugs, warning that the virus can cause potentially life-threatening viral 
pneumonia much more commonly than the typical flu, sometimes in relatively 
young, otherwise healthy people. "It's not like seasonal influenza," said 
Nikki Shindo, a medical officer in the WHO's Epidemic and Pandemic Alert 
and Response Department. "It can cause very severe disease in previously 
healthy young adults." Shindo's comments came at the conclusion of a 
special 3 day meeting in Washington of more than 100 experts from around 
the world. WHO called the meeting to review the latest research on the new 
H1N1 virus [the pandemic (H1N1) 2009 virus] and to revise guidelines for 
treating the infection [see part [2] below}.

Unlike the seasonal flu, Shindo said, the virus appears more likely to 
travel deep into the lungs, where it can cause viral pneumonia. Such a 
condition can cause severe lung damage and a life threatening condition 
known as acute respiratory distress syndrome. "Remarkably different is this 
small subset of patients that presents very severe viral pneumonia," Shindo 
said. Shindo noted that some hospitals in Australia and New Zealand were 
severely strained by seriously ill swine flu patients during their recently 
ended winter.

"This disease overwhelmed emergency rooms and especially intensive care 
units because of the very severe patients that required special care," 
Shindo said, urging hospitals to prepare for the possibility of a 
significant number of patients requiring intensive care. "We can expect 
more severe disease during the upcoming influenza season," she said. Shindo 
noted that, although a few cases have been reported of people who have been 
infected with virus that is resistant to antiviral drugs, the medications 
remain highly effective for most patients if administered quickly. "Do not 
delay treatment," Shindo said. "Do not miss this opportunity for early 
treatment."

WHO's warnings came as US health officials announced that the number of 
states reporting widespread flu had increased from 37 to 41 and regional or 
local outbreaks were being reported in the remaining parts of the country. 
The number of deaths from pneumonia and flu-like illnesses had surpassed 
what the federal Centers for Disease Control and Prevention (CDC) considers 
an epidemic level, said Anne Schuchat of CDC. About 6 per cent of all 
doctor visits are for flu-like illnesses, she said. "It's unprecedented for 
this time of year to see the whole country seeing such high level of 
activity," she said.

CDC also reported that vaccine production was proceeding slower than 
officials had hoped, meaning less vaccine was probably going to be 
available by the end of the month than originally projected. While 
officials had hoped about 40 million doses would be available by the end of 
October [2009], that would probably fall short by about 10 million to 12 
million doses, Schuchat said. "We do still expect to have the large number 
of doses," Schuchat said. "Eventually anyone who wants to be vaccinated 
will be able to be vaccinated. But it's a slow start. We unfortunately 
won't have as much by the end of this month as we had hoped." So far 11.4 
million doses have become available and states have ordered about 8 million 
doses, but large amounts of vaccine will not become available until 
November [2009], she said.

The number of children and teenagers who have died from the disease 
continued to mount, Schuchat said. At least 86 Americans younger than 18 
have died from the disease, including 11 deaths that have been reported in 
the past week. About half of the deaths that have occurred in the past 
month were among teenagers, she said. Since 30 Aug 2009, 43 pediatric 
deaths have been reported, including 3 in those younger than age 2; 5 among 
those ages 2 to 4, 16 in those ages 5 to 11; and 19 among those ages 12 to 
17, she said. "These are very sobering statistics," Schuchat said, noting 
that only about 40 or 50 children die during an entire flu season. While 
many of the deaths occurred among those with other health problems, some 
occurred in children who were otherwise healthy, she said. "Every death we 
take seriously, but as a society the deaths of children are very hard to 
take," she said.

[byline: Rob Stein]

-- 
communicated by:
ProMED-mail
<promed@promedmail.org>

******
[2]
Date: Fri 16 Oct 2009
Source: World Health Organization (WHO), CSR [edited]
<http://www.who.int/csr/disease/swineflu/notes/h1n1_clinical_features_20091016/en/index.html>


Clinical features of severe cases of influenza pandemic (H1N1) 2009 virus 
infection
Briefing note 13
-------------------------------------------------------
To gather information about the clinical features and management of 
pandemic influenza, WHO hosted a 3 day meeting at the headquarters of the 
Pan American Health Organization in Washington DC, on 14 Oct 2009. Findings 
and experiences were presented by around 100 clinicians, scientists, and 
public health professionals from the Americas, Europe, Asia, Africa, the 
Middle East, and Oceania.

The meeting confirmed that the overwhelming majority of persons worldwide 
infected with the new pandemic (H1N1) 2009 virus continue to experience 
uncomplicated influenza-like illness, with full recovery within a week, 
even without medical treatment.

However, concern is now focused on the clinical course and management of 
small subsets of patients who rapidly develop very severe progressive 
pneumonia. In these patients, severe pneumonia is often associated with 
failure of other organs, or marked worsening of underlying asthma or 
chronic obstructive airway disease. Treatment of these patients is 
difficult and demanding, strongly suggesting that emergency rooms and 
intensive care units will experience the heaviest burden of patient care 
during the pandemic.

Primary viral pneumonia is the commonest finding in severe cases and a 
frequent cause of death. Secondary bacterial infections have been found in 
about 30 per cent of fatal cases. Respiratory failure and refractory shock 
have been the commonest causes of death. Presentations during the meeting 
explored the pathology of severe disease in detail, with findings supported 
by work in experimental animals. These findings confirm the ability of the 
pandemic (H1N1) 2009 virus to directly cause severe pneumonia.

Participants who have managed such cases agreed that the clinical picture 
in severe cases is strikingly different from the disease pattern seen 
during epidemics of seasonal influenza. While people with certain 
underlying medical conditions, including pregnancy, are known to be at 
increased risk, many severe cases occur in previously healthy young people. 
In these patients, predisposing factors that increase the risk of severe 
illness are not presently understood, though research is under way. In 
severe cases, patients generally begin to deteriorate around 3 to 5 days 
after symptom onset. Deterioration is rapid, with many patients progressing 
to respiratory failure within 24 hours, requiring immediate admission to an 
intensive care unit. Upon admission, most patients need immediate 
respiratory support with mechanical ventilation. Some patients do not 
respond well to conventional ventilatory support, however, further 
complicating the treatment.

On the positive side, findings presented during the meeting add to a 
growing body of evidence that prompt treatment with the antiviral drugs, 
oseltamivir or zanamivir, reduces the severity of illness and improves the 
chances of survival. These findings strengthen previous WHO recommendations 
for early treatment with these drugs for patients who meet treatment 
criteria, even in the absence of a positive confirmatory test.

In addition to pneumonia directly caused by replication of the virus, 
evidence shows that pneumonia caused by co-infection with bacteria can also 
contribute to a severe, rapidly progressive illness. Bacteria frequently 
reported include _Streptococcus pneumoniae_ and _Staphylococcus aureus_, 
including methicillin-resistant strains in some cases. As these bacterial 
co-infections are more frequent than initially recognized, clinicians 
stressed the need to consider empiric antimicrobial therapy for community 
acquired pneumonia as an early treatment.

Participants agreed that the risk of severe or fatal illness is highest in 
3 groups: pregnant women, especially during the 3rd trimester of pregnancy, 
children younger than 2 years of age, and people with chronic lung disease, 
including asthma. Neurological disorders can increase the risk of severe 
disease in children.

Evidence presented during the meeting further shows that disadvantaged 
populations, such as minority groups and indigenous populations, are 
disproportionately affected by severe disease. Although the reasons for 
this heightened risk are not yet fully understood, theories being explored 
include the greater frequency of co-morbidities, such as diabetes and 
asthma, often seen in these groups, and lack of access to care.

Although the exact role of obesity is poorly understood at present, obesity 
and especially morbid obesity have been present in a large portion of 
severe and fatal cases. Obesity has not been recognized as a risk factor in 
either past pandemics or seasonal influenza.

WHO and its partners are providing technical guidance and practical support 
to help developing countries better detect and treat illness caused by the 
pandemic virus. Patient care advice that can be applied in resource-limited 
settings is being rapidly compiled.

-- 
communicated by:
a correspondent who has requested anonymity

[Most people worldwide infected with the pandemic (H1N1) 2009 virus 
continue to experience uncomplicated influenza-like illness. But both 
pneumonia directly caused by replication of the virus, and pneumonia caused 
by co-infection with bacteria, can contribute to a severe rapidly 
progressive sometimes fatal illness. Risk of severe or fatal illness is 
highest but not exclusively so in 3 groups: pregnant women, especially 
during the 3rd trimester of pregnancy, children younger than 2 years of 
age, and people with chronic lung disease, including asthma. However, the 
factors predisposing apparently healthy young people to severe disease have 
yet to be defined. - Mod.CP]

[see also:
Influenza pandemic (H1N1) 2009 (71): case counts 20091017.3568
Influenza pandemic (H1N1) 2009 (70): Nepal 20091016.3563
Influenza pandemic (H1N1) 2009 (69): case management 20091013.353
Influenza pandemic (H1N1) 2009 (68): Viet Nam, virus clearance 20091011.3519
Influenza pandemic (H1N1) 2009 (67): vaccine delivery 20091011.3515
Influenza pandemic (H1N1) 2009 (66): case counts 20091010.3510
Influenza pandemic (H1N1) 2009 (65): update 20091009.3495
Influenza pandemic (H1N1) 2009 (64): Canada, vaccination update 20091005.3457
Influenza pandemic (H1N1) 2009 (63): USA military vaccine 20091002.3437
Influenza pandemic (H1N1) 2009 (62): Taiwan hosp cases 20091001.3421
Influenza pandemic (H1N1) 2009 (61): FLAARDS 20091001.3419
Influenza pandemic (H1N1) 2009 (60): bacterial coinfection 20090930.3410
Influenza pandemic (H1N1) 2009 (50): oseltamivir-resistance 20090917.3260
Influenza pandemic (H1N1) 2009 (40): global update 20090906.3138
Influenza pandemic (H1N1) 2009 (30): assumptions 20090813.2879
Influenza pandemic (H1N1) 2009 (20): Peru, 33 percent asymptomatic 
20090730.2668
Influenza pandemic (H1N1) 2009 (10): vaccine 20090720.2577
Influenza pandemic (H1N1) 2009 - Viet Nam: patient data 20090708.2450]

..................cp/ejp/sh



*##########################################################*
************************************************************
ProMED-mail makes every effort to  verify  the reports  that
are  posted,  but  the  accuracy  and  completeness  of  the
information,   and  of  any  statements  or  opinions  based
thereon, are not guaranteed. The reader assumes all risks in
using information posted or archived by  ProMED-mail.   ISID
and  its  associated  service  providers  shall not be  held
responsible for errors or omissions or  held liable for  any
damages incurred as a result of use or reliance upon  posted
or archived material.
************************************************************
Become     a    ProMED-mail    Premium     Subscriber     at
<http://www.isid.org/ProMEDMail_Premium.shtml>
************************************************************
Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send  all  items  for   posting  to:   promed@promedmail.org

(NOT to  an  individual moderator).  If you do not give your
full name and  affiliation, it  may  not  be  posted.   Send
commands  to  subscribe/unsubscribe,   get  archives,  help,
etc. to: majordomo@promedmail.org.    For assistance  from a
human  being  send  mail  to:   owner-promed@promedmail.org.

############################################################
############################################################

about ISID | membership | programs | publications | resources
14th ICID | site map | ISID home

©2001,2009 International Society for Infectious Diseases
All Rights Reserved.
Read our privacy guidelines.
Use of this web site and related services is governed by the Terms of Service.